Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytek Biosciences (CTKB) Cost of Revenue (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Cost of Revenue for 6 consecutive years, with $60.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cost of Revenue rose 154.89% year-over-year to $60.7 million, compared with a TTM value of $97.0 million through Dec 2025, up 38.66%, and an annual FY2025 reading of $97.0 million, up 8.6% over the prior year.
  • Cost of Revenue was $60.7 million for Q4 2025 at Cytek Biosciences, up from $11.7 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $60.7 million in Q4 2025 and bottomed at -$4.0 million in Q3 2021.
  • Average Cost of Revenue over 5 years is $16.6 million, with a median of $12.5 million recorded in 2024.
  • The sharpest move saw Cost of Revenue tumbled 142.65% in 2021, then surged 436.75% in 2022.
  • Year by year, Cost of Revenue stood at $8.3 million in 2021, then skyrocketed by 128.35% to $19.0 million in 2022, then skyrocketed by 78.95% to $33.9 million in 2023, then decreased by 29.79% to $23.8 million in 2024, then skyrocketed by 154.89% to $60.7 million in 2025.
  • Business Quant data shows Cost of Revenue for CTKB at $60.7 million in Q4 2025, $11.7 million in Q3 2025, and $12.1 million in Q2 2025.